Leap Therapeutics

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to acquiring and developing innovative cancer therapies. The company specializes in targeted antibody treatments, focusing on inhibiting tumor-promoting pathways and enhancing immune responses against cancer cells. Its lead program, DKN-01, is a monoclonal antibody that targets Dickkopf-related protein 1 and is currently undergoing clinical trials for various cancers, including esophagogastric, gynecologic, and colorectal cancers. In addition to DKN-01, Leap Therapeutics is developing FL-301, which targets Claudin18.2-expressing cells, as well as two preclinical antibody programs, FL-302 and FL-501. Founded in 2011 and previously known as HealthCare Pharmaceuticals, the company aims to advance therapies that address critical needs in oncology.

http://www.leaptx.com

https://app.dealroom.co/companies/leap_therapeutics

https://crunchbase.com/organization/leap-therapeutics

https://facebook.com/leaptx

https://linkedin.com/company/leap-therapeutics

https://twitter.com/leaptherapeutic

https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=118044172

Gus Lawlor

COO

1 past transactions

MacroCure

Acquisition in 2016

MacroCure is a biotechnology company focused on the development and commercialization of advanced cell therapy products. The company's first focus of interest is in the arena of wound care. The technology employs activated white blood cells obtained from young adults healthy donor blood. The activated cells provide the natural environment for wound healing, and ensure that necessary cell activities and factor secretions are maintained as required for wound healing. This novel concept is the first of its kind in the field of wound therapy.

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.